PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
- Yoichi Nagata, K. Lan, Dihua Yu
- Biology, ChemistryCancer Cell
- 1 April 2004
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
- C. Liedtke, C. Mazouni, L. Pusztai
- Medicine, BiologyJournal of Clinical Oncology
- 10 March 2008
Patients with TNBC have increased pCR rates compared with non-TNBC, and those with pCR have excellent survival, however, patients with RD after neoadjuvant chemotherapy have significantly worse survival if they have TNBC compared with other patients, particularly in the first 3 years.
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
- J. Baselga, M. Campone, G. Hortobagyi
- Medicine, BiologyNew England Journal of Medicine
- 8 February 2012
Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromat enzyme inhibitors.
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
- W. Symmans, F. Peintinger, L. Pusztai
- MedicineJournal of Clinical Oncology
- 1 October 2007
Residual cancer burden was calculated as a continuous index combining pathologic measurements of primary tumor and nodal metastases and was a significant predictor of distant relapse-free survival (DRFS) in multivariate Cox regression analyses.
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
- R. Rouzier, C. Perou, L. Pusztai
- Medicine, BiologyClinical Cancer Research
- 15 August 2005
The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin-containing preoperative chemotherapy than the luminal and normal-like cancers.
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene…
It is shown that EGF induces EGFR-expressing cancer cells to undergo a transition from the epithelial to the spindle-like mesenchymal morphology and induce cancer cell EMT via STAT3-mediated TWIST gene expression.
ESR1 ligand binding domain mutations in hormone-resistant breast cancer
- Weiyi Toy, Yang Shen, S. Chandarlapaty
- BiologyNature Genetics
- 3 November 2013
A comprehensive genetic analysis of two independent cohorts of metastatic ER-positive breast tumors and identified mutations in ESR1 affecting the ligand-binding domain (LBD) in 14 of 80 cases that implicate LBD-mutant forms of ER in mediating clinical resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation
- Jer-Yen Yang, C. S. Zong, M. Hung
- Biology, ChemistryNature Cell Biology
- 1 February 2008
This study elucidates a novel pathway in cell growth and tumorigenesis through negative regulation of FOXO3a by RAS–ERK and MDM2 and downregulates Forkhead box O 3a by directly interacting with and phosphorylating FOXO 3a at Ser 294, Ser 344 and Ser 425.
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
- K. Hess, K. Anderson, L. Pusztai
- MedicineJournal of Clinical Oncology
- 10 September 2006
A 30-probe set pharmacogenomic predictor predicted pCR to T/FAC chemotherapy with high sensitivity and negative predictive value.
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
- C. Hatzis, L. Pusztai, W. Symmans
- Medicine, BiologyJAMA
- 11 May 2011
A genomic predictor combining ER status, predicted Chemoresistance, predicted chemosensitivity, and predicted endocrine sensitivity identified patients with high probability of survival following taxane and anthracycline chemotherapy.
...
...